We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Malaria Severity Not Determined Solely by Parasitemia

By LabMedica International staff writers
Posted on 26 May 2014
The relative contributions of such factors as the concentration level of malaria-causing parasites in a person's blood to disease severity and to development of protective immunity are not adequately understood. More...


In areas where transmission is stable, severe malaria is unlikely to occur after five years of age, presumably as a result of immunity, and mathematical models suggest that protection against noncerebral severe malaria develops after one or two infections.

A team of international scientists led by those at the US National Institutes of Health (Rockville, MD, USA) enrolled 882 newborns in the study as part of a longitudinal birth cohort between September 2002 and November 2005, in Muheza (Tanzania). Children were followed for an average of two years and for as long as four years. Children were examined at birth, once every two weeks during infancy, once every month after infancy, and during any illness. Blood smears were collected at all visits, regardless of whether symptoms were present.

Parasitemia was defined as any Plasmodium falciparum detected in a Giemsa-stained blood smear, and high-density infection requiring parenteral treatment was defined as a parasite density of more than 2,500 parasites per 200 white cells. P. falciparum-specific histidine-rich protein 2 plasma concentrations were determined during infection in all available samples from the cohort, which included 475 samples from the children who suffered severe malaria. Samples were tested using an in-house double-site sandwich enzyme-linked immunosorbent assay (ELISA). Hemoglobin type (HbAA, HbAS, and HbSS) was determined by cellulose acetate paper electrophoresis (Helena Laboratories; Beaumont, Texas, USA).

The scientist found that no simple relationship between parasite density and malaria severity emerged. Of the 102 children who did develop severe malaria at least once while enrolled in the study, almost two-thirds had high parasite density, but only mild disease either before or after the episode of severe malaria. This data suggest that one or two mild episodes of malaria are not sufficient to eliminate the risk of severe malaria which is contrary to predictions made by some mathematical models. The team noted that this prospective study is the first to provide direct evidence that severe malaria risk is stable over several infections.

The authors concluded they have provided direct evidence that severe malaria is unlikely to recur but that it commonly occurs after previous infections, including high-density infections. The immunity to severe malaria is not related to improved control of parasite density. The epidemiologic evidence suggests that naturally acquired immunity targets a conserved feature of the various severe-malaria syndromes, such as parasite virulence or host inflammation. The study was published on May 8, 2014, in the New England Journal of Medicine (NEJM).

Related Links:
National Institutes of Health 
Helena Laboratories 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
HPV Test
Allplex HPV28 Detection
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Molecular Diagnostics

view channel
Image: Graphical Abstract (Image Credit: Cheng N, Ouellette TW, Skead K, et al. Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection. Cell Genomics (2026). DOI:10.1016/j.xgen.2026.101364)

Blood Test Stratifies Prostate and Breast Cancer Risk Years Before Diagnosis

Cancer is the second leading cause of death globally, and late diagnosis contributes substantially to mortality. Routine screening is available for only a few cancer types, while other early detection... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.